Finding Little Relief In the Drug Market
38293
And so we said goodbye this year to an illusion -- that the drugs we need will be waiting for us when we need them, safe and sound.
167084
Scientists have discovered a genetic variation that may help explain why some people who develop the condition get no relief from drug treatments.
140996
A day late and possibly several millions of dollars short. That's the scenario facing one drug manufacturer unless it can get a helping hand from Congress.
759798
Drug distributors would like to forget 2004. But this may mean bargains for investors.
220858
Illegal psychedelic drugs, long disparaged as medically useless, are increasingly being studied as effective treatments for anxiety and other emotional disorders.
692929
Some drugmakers are hitting a slump, but not all of them. Which ones can still cure what ails your portfolio?
739351
A frighteningly expensive drug of marginal efficacy begets triple-digit multiples? Bring on the miracles.
492704
Intensive marketing has helped create blockbuster drugs that aren't necessarily more effective than cheaper alternatives.
348531
That would be small consolation to pharma investors.
259812
The pharmaceutical enlists help to thwart a troublesome illness.
227227
Fear about addiction leads millions of people to go without pain medicines that are safe, effective and cheap.
200045
THE REGION Study: Uninsured pay highest drug prices
436158
Many cannot easily shop around for the best bargains on their drugs, as other Medicare beneficiaries are supposed to do.
79317
This has not been an especially good year for regulatory government agencies, with their accompanying acronyms. Let&#39;s begin with the Food and Drug Administration (FDA), which can&#39;t quite make up its mind which drug will kill us first - or how quickly.
109891
The troubles surrounding a major class of painkillers may ultimately help cure what has long ailed the US Food and Drug Administration.
243349
This lung cancer drug is not as effective as once hoped.
278626
The company reports mediocre earnings as investors remain nervous about the drug sector.